Investigational drug · Phase 2
SYH2085
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Influenza.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SYH2085"
First trial start
2026
Oct 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYH2085", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "SYH2085" as an intervention, largest first.
- A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza.Pivotal-lookingNot yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07798193 · 213 participants (planned) · Start Oct 10, 2026 · Primary completion Apr 30, 2027
Drug: SYH2085; Placebo · For: Influenza
- A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07412353 · 74 participants (planned) · Start Jan 12, 2026 · Primary completion Nov 12, 2026
Drug: SYH2085; Placebo · For: Healthy Participants
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Influenza
- Investigational Influenza VaccinePhase 34 trials
BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)
- GP681Phase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- GP681 SimulantPhase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- BRC-201TG-1000, Pixavir MarboxilPhase 31 trial
Boryung Biopharma Co., Ltd. · Influenza
- mRNA-1018-H5Phase 31 trial
Moderna · Influenza
- Fluzone QudrivalentPhase 22 trials
Sanofi · Healthy Volunteers, Influenza Immunization, Influenza
- TRX-100Phase 22 trials
Traws Pharma, Inc. · Influenza
- ApomivirFE-L-APO, drug substancePhase 21 trial
Far East Bio-Tec Co., Ltd · Influenza
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.